Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments
Open Access
- 1 June 2011
- journal article
- review article
- Published by Taylor & Francis Ltd in OncoTargets and Therapy
- Vol. 4, 79-96
- https://doi.org/10.2147/OTT.S14107
Abstract
Peer reviewed article authored by (Gupta SG, Carballido ES, Fishman M). Read article or submit your manuscript for publishing.Keywords
This publication has 85 references indexed in Scilit:
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401Journal of Clinical Oncology, 2012
- Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other TumorsCancer Biotherapy & Radiopharmaceuticals, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2010
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune ResponsesJournal of Biomedicine and Biotechnology, 2010
- Phase I Clinical Trial of an Adenovirus/Prostate-Specific Antigen Vaccine for Prostate Cancer: Safety and Immunologic ResultsClinical Cancer Research, 2009
- PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia modelBlood, 2009
- Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood, 2009
- Endothelial Nitric Oxide Synthase Mediates Lymphangiogenesis and Lymphatic MetastasisCancer Research, 2009
- Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic CarcinomaClinical Cancer Research, 2008